News und Analysen
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Key Points
- Interested in Inovio Pharmaceuticals, Inc.? Here are five stocks we like better.
- Shareholders approved all proposals at Inovio’s 2026 annual meeting, including the election of eight
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte plans to start a Phase 3 trial of mutant CALR antibody 989 in essential thrombocythemia around
EQS-News: Fresenius-Hauptversammlung 2026: Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen's diranersen missed its primary endpoint in the Phase 2 CELIA trial, sending BIIB shares down more than 10% on
EQS-Adhoc: Neubesetzung des Vorstandsvorsitzes der Carl Zeiss Meditec AG
EQS-News: Hauptversammlung 2026: Fresenius blickt auf sehr gutes Geschäftsjahr 2025 zurück und schlägt 5% mehr Dividende vor
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Key Points
- Interested in Climb Bio, Inc.? Here are five stocks we like better.
- Budoprutug, Climb Bio’s CD19-targeting antibody, is the company’s lead asset, with early data showing complete
Analog Devices Q2 Earnings Call Highlights
Key Points
- Interested in Analog Devices, Inc.? Here are five stocks we like better.
- Analog Devices posted record fiscal Q2 2026 results, with revenue of $3.62 billion, non-GAAP EPS of $3.09
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
Key Points
- Interested in Arrowhead Pharmaceuticals, Inc.? Here are five stocks we like better.
- REDEMPLO is gaining momentum, with approvals in the U.S., China, Australia and Canada already in
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Key Points
- Interested in Adagene Inc. Sponsored ADR? Here are five stocks we like better.
- Adagene’s lead drug ADG126 (muzastotug) is a masked anti-CTLA-4 antibody designed to improve the
BeyondTrust wurde im „KuppingerCole Analysts Leadership Compass 2026“ zum sechsten Mal in Folge als „Overall Leader“ im Bereich Privileged Access Management ausgezeichnet
- Als führendes Unternehmen in den Bereichen Produkt, Innovation und Marktführerschaft anerkannt
- Hervorzuheben sind fortschrittlicher JIT- und temporärer Zugriff, KI-Agenten-Governance, ein
Neue Studie im Auftrag von Vertex: Fehlende Abstimmung zwischen IT, Steuerabteilung und Finanzwesen bedroht Umsatz(volumen) in Unternehmen
Nur 12 % der Unternehmen weltweit verfügen über vollständig integrierte Steuertechnologie, zusätzlich entwickelt sich Echtzeit-Compliance zu einem geschäftskritischen Erfolgsfaktor
KING OF PRUSSIA
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte’s CEO says the company’s post-Jakafi growth path is becoming clearer as its commercial business
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for
Novartis Aktie: 9,4 Prozent Plus seit Jahresbeginn
Der Schweizer Pharmakonzern Novartis setzt seine Erholungsbewegung fort. Die Aktie notiert am Freitag bei…
Der Beitrag Novartis Aktie: 9,4 Prozent Plus seit Jahresbeginn erschien zuerst auf kapitalm
Tamboran Resources Q3 Earnings Call Highlights
Tamboran Resources (NYSE:TBN) said it remains on track to deliver first gas from its Beetaloo Basin pilot project in the third quarter of the calendar year, as the company highlighted farm-out
STERIS Q4 Earnings Call Highlights
STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum
Bayer Aktiengesellschaft (ETR:BAYN) executives said the company’s Crop Science division remains on track with a five-year plan centered on cost savings